For the full scientific overview, see What Is Semaglutide
Among people who were prescribed a GLP-1 medication for weight loss such as semaglutide (branded as Ozempic and Wegovy), exenatide (Byetta) and liraglutide (Victoza) 10 out of every 10,000, or 0.1%, were diagnosed with gastroparesis at least six months later
The office checks the denial reason usually one of a small set and either resubmits with the missing documentation or asks the patient to schedule a follow-up to gather what was missing the first time
Oregon, Washington, Idaho, and Utah Medicaid programs cover SGLT-2 inhibitors for T2D
Glutathione and Related Molecules in Parkinsonism
Kaiser Permanente Northwest, prior authorization criteria for GLP-1 anti-obesity agents California Medi-Cal dropped GLP-1 obesity coverage effective January 1, 2026, eliminating the weight-loss Wegovy pathway for Kaiser Medi-Cal members in California